SCHEMBL20211740

SCHEMBL20211740

O=C(O)c1cccc(-c2cn3c(=O)c(Cc4ccco4)nc-3c(Cc3ccccc3)[nH]2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.39
▸ SMN1; SMN2 Q16637 4/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ ADORA2B P29275 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ F2 P00734 1/20 0.35
▸ ACMSD Q8TDX5 3/20 0.35
▸ TSHR P16473 3/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ HRH2 P25021 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ EGLN1 Q9GZT9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30800214 1.00 KEAP1 (0.39) KEAP1SMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL20211769 0.90 TSHR (0.36) SMN1; SMN2ALDH1A1KDM4EHPGDADORA2B
SCHEMBL19810232 0.90 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1KDM4EADORA2BHSD17B10
SCHEMBL30110483 0.90 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1KDM4EADORA2BHSD17B10
SCHEMBL2670126 0.89 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDADORA2BHSD17B10
SCHEMBL20211734 0.89 MAOA (0.39) SMN1; SMN2ALDH1A1KDM4EHPGDNPC1
SCHEMBL25760270 0.88 ADORA2B (0.38) SMN1; SMN2ALDH1A1KDM4EHPGDNPC1
SCHEMBL27213496 0.88 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1KDM4EHPGDADORA2B
SCHEMBL19810311 0.88 ADORA2A (0.35) SMN1; SMN2ALDH1A1ADORA2BHSD17B10TSHR
SCHEMBL19810310 0.87 ADORA2B (0.38) ALDH1A1KDM4EHPGDADORA2BHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4279490-A2 CELL IMPERMEABLE COELENTERAZINE ANALOGUES Promega Corporation (US) 2023-11-22 — — EP claimed
EP-3841173-A1 COELENTERAZINE ANALOGUES Promega Corporation (US) 2021-06-30 — — EP claimed
CN-112513188-A Coelenterazine analogs 普洛麦格公司 2021-03-16 — — CN claimed
US-10577370-B2 Cell impermeable coelenterazine analogues PROMEGA CORPORATION (US) 2020-03-03 — — US claimed
US-20200062766-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2020-02-27 — — US claimed
WO-2020041579-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2020-02-27 — — WO claimed
EP-3548492-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES Promega Corporation (US) 2019-10-09 — — EP claimed
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-06-07 — — US claimed
WO-2018102693-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2018-06-07 — — WO claimed
US-20240059697-A1 COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2024-02-22 — — US disclosed
CN-112513188-B Coelenterazine analogs 普洛麦格公司 2024-01-26 — — CN disclosed
EP-4279490-A2 CELL IMPERMEABLE COELENTERAZINE ANALOGUES Promega Corporation (US) 2023-11-22 — — EP disclosed
EP-3548492-B1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORP (US) 2023-07-05 — — EP disclosed
EP-3548492-B1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORP (US) 2023-07-05 — — EP disclosed
EP-3548492-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES Promega Corporation (US) 2019-10-09 — — EP disclosed
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-06-07 — — US disclosed
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-06-07 — — US disclosed
WO-2018102693-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2018-06-07 — — WO disclosed
WO-2018102693-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2018-06-07 — — WO disclosed
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200062766-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 KEAP1 1010/4885SMN1; SMN2 3970/4885ALDH1A1 3541/4885
US-10577370-B2 Cell impermeable coelenterazine analogues SI, GLB1, MRPL21 KEAP1 864/4885SMN1; SMN2 3924/4885ALDH1A1 3715/4885
US-20240059697-A1 COELENTERAZINE ANALOGUES GLB1, SI, TCF7L2 KEAP1 1010/4885SMN1; SMN2 3970/4885ALDH1A1 3541/4885
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES SI, GLB1, MRPL21 KEAP1 864/4885SMN1; SMN2 3924/4885ALDH1A1 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback